Genomic Health Q1 Revenues Jump 19 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Wednesday that its first quarter revenues were up 19 percent percent year over year, driven primarily by continued growth in test volume, mainly in breast cancer, but also in prostate cancer.

The Redwood City, California-based molecular diagnostics firm brought in total revenues of $80.9 million for the three months ended March 31, up from $68.2 million in the first quarter of 2015, and beating the consensus Wall Street estimate of $78.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.

Mar
23
Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.

Mar
28

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Apr
18
Sponsored by
Twist BioScience

This webinar will cover methodologies for genome-wide screening with CRISPR/Cas9 in human pluripotent stem cells (hPSCs).